Pathogen‐reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola‐specific neutralizing antibodies

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Vox Sanguinis

• Publication date

  2016-01-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/vox.12376PMID 26766162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ebola Virus

  2018cited by this paper
• Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

  2016cited by this paper
• Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.

  2015cited by this paper
• Ebola virus disease complicated with viral interstitial pneumonia: a case report

  2015cited by this paper
• Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease.

  2015cited by this paper
• Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa

  2015cited by this paper
• Commentary: Management of Microbiological Samples in a Confirmed Case of Ebola Virus Disease: Constraints and Limitations

  2015cited by this paper
• Possible Sexual Transmission of Ebola Virus — Liberia, 2015

  2015cited by this paper
• Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States

  2015cited by this paper
• Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care.

  2015cited by this paper
• Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors

  2015cited by this paper
• Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries

  2015cited by this paper
• The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States.

  2015cited by this paper
• Emergence of Zaire Ebola virus disease in Guinea.

  2014cited by this paper
• Ebola Virus Disease Cases Among Health Care Workers Not Working in Ebola Treatment Units — Liberia, June–August, 2014

  2014cited by this paper
• Ebola raises profile of blood-based therapy

  2014cited by this paper
• Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

  2014cited by this paper
• Structures of protective antibodies reveal sites of vulnerability on Ebola virus

  2014cited by this paper
• The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

  2014cited by this paper
• Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections.

  2014cited by this paper
• International community ramps up Ebola vaccine effort.

  2014cited by this paper
• Dynamics and control of Ebola virus transmission in Montserrado, Liberia: a mathematical modelling analysis.

  2014cited by this paper
• The first case of Ebola virus disease acquired outside Africa.

  2014cited by this paper
• Ebola virus convalescent blood products: Where we are now and where we may need to go

  2014cited by this paper
• Clinical care of two patients with Ebola virus disease in the United States.

  2014cited by this paper
• A dose of reality.

  2014cited by this paper
• Response to Importation of a Case of Ebola Virus Disease — Ohio, October 2014

  2014cited by this paper
• Update on the use of pathogen‐reduced human plasma and platelet concentrates

  2013cited by this paper
• Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).

  2013cited by this paper
• Transfusion safety in francophone African countries: an analysis of strategies for the medical selection of blood donors

  2012cited by this paper
• Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.

  2011cited by this paper
• Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection

  2011cited by this paper
• Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms

  2010cited by this paper
• Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion

  2009cited by this paper
• Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers

  2008cited by this paper
• Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function

  2006cited by this paper
• Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients

  2004cited by this paper
• A dose of reality

  2004cited by this paper
• Clinical recognition and management of patients exposed to biological warfare agents.

  2001cited by this paper
• Passive immunity in prevention and treatment of infectious diseases.

  2000cited by this paper
• Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.

  1999cited by this paper
• Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection

  1999cited by this paper
• Clinical recognition and management of patients exposed to biological warfare agents.

  1997cited by this paper
• [Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases].

  1986cited by this paper

• Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

  2022cites this paper
• The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

  2021cites this paper
• Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma

  2021cites this paper
• Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency

  2021cites this paper
• Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?

  2020cites this paper
• Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in human plasma

  2020cites this paper
• Transfusion reactions associated with COVID‐19 convalescent plasma therapy for SARS‐CoV‐2

  2020cites this paper
• Impact of pathogen reduction technologies on immunological propertiesof the COVID-19 convalescent plasma

  2020cites this paper
• Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy

  2019cites this paper
• Anti-Ebola therapy for patients with Ebola virus disease: a systematic review

  2019cites this paper
• Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: A joint publication from the AABB and the International Society of Cell Therapy.

  2019cites this paper
• Epidemiological Trends and Current Challenges in Ebola: Pathogen Biology, Drug Targets, and Therapeutic Strategies

  2019cites this paper
• Filovirus – Auslöser von hämorrhagischem Fieber

  2018cites this paper
• Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus

  2018cites this paper
• Convalescent Plasma and the Dose of Ebola Virus Antibodies.

  2017cites this paper
• Use of convalescent plasma in Ebola virus infection.

  2017cites this paper
• Wirus EBOLA jako potencjalne wyzwanie dla krwiodawstwa, krwiolecznictwa i zdrowia publicznego

  2017cites this paper
• Transfusionsmedizinische Versorgung von Patienten mit Ebolavirus-Infektion

  2016cites this paper
• Convalescent Ebola plasma: assessing neutralizing antibodies at the right stage

  2016cites this paper
• Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future

  2016cites this paper